Perrigo's Q4 Earnings Beat Estimates, Revenues Decline Y/Y

Core Insights - Perrigo Company plc (PRGO) reported adjusted earnings of 93 cents per share in Q4 2024, surpassing the Zacks Consensus Estimate of 92 cents, marking an 8% year-over-year increase due to improved margins and lower variable expenses [1] - Net sales for the quarter declined 1.6% year over year to $1.14 billion, falling short of the Zacks Consensus Estimate of $1.20 billion, primarily due to lost sales from exited businesses and product lines [1][2] - For the full year 2024, Perrigo's revenues totaled $4.37 billion, a decrease of 6.1% year over year, with adjusted earnings of $2.57 per share, down 0.4% from the previous year [7] Sales Performance - In the Consumer Self Care Americas (CSCA) segment, net sales were flat year over year at $744 million, with growth in Nutrition, Skin Care, and Women's Health categories offset by declines in Pain & Sleep Aids, Upper Respiratory, and Digestive Health categories [5] - The Consumer Self Care International (CSCI) segment reported net sales of $394 million, down 4.5% year over year due to product line exits and unfavorable currency movements, although organic sales increased by 1.8% [6] Future Outlook - Perrigo is set to host a virtual Investor Day to present its strategic plan for 2025-2027 and provide financial guidance for the full year 2025 [8]